COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

NASDAQ:CLGN • IL0004960188

0.634 USD
-0.09 (-11.93%)
At close: Feb 17, 2026
0.6 USD
-0.03 (-5.36%)
After Hours: 2/17/2026, 8:06:19 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, CLGN scores 3 out of 10 in our fundamental rating. CLGN was compared to 521 industry peers in the Biotechnology industry. The financial health of CLGN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CLGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CLGN has reported negative net income.
  • CLGN had a negative operating cash flow in the past year.
  • CLGN had negative earnings in 4 of the past 5 years.
  • In the past 5 years CLGN reported 4 times negative operating cash flow.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • CLGN's Return On Assets of -86.31% is on the low side compared to the rest of the industry. CLGN is outperformed by 70.63% of its industry peers.
  • The Return On Equity of CLGN (-130.68%) is worse than 61.42% of its industry peers.
Industry RankSector Rank
ROA -86.31%
ROE -130.68%
ROIC N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

  • CLGN has a better Gross Margin (63.03%) than 79.27% of its industry peers.
  • CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CLGN has about the same amout of shares outstanding than it did 1 year ago.
  • CLGN has more shares outstanding than it did 5 years ago.
  • CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.04, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
  • CLGN's Altman-Z score of -13.04 is on the low side compared to the rest of the industry. CLGN is outperformed by 76.97% of its industry peers.
  • CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.04
ROIC/WACCN/A
WACC8.73%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 3.66 indicates that CLGN has no problem at all paying its short term obligations.
  • The Current ratio of CLGN (3.66) is comparable to the rest of the industry.
  • A Quick Ratio of 3.45 indicates that CLGN has no problem at all paying its short term obligations.
  • CLGN has a Quick ratio (3.45) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.66
Quick Ratio 3.45
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CLGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
  • The Revenue has grown by 280.77% in the past year. This is a very strong growth!
  • CLGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.99% yearly.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.95%
Revenue 1Y (TTM)280.77%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1825%

3.2 Future

  • Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.70% on average per year.
  • The Revenue is expected to grow by 103.99% on average over the next years. This is a very strong growth
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year422.12%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • CLGN's earnings are expected to grow with 25.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CLGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (2/17/2026, 8:06:19 PM)

After market: 0.6 -0.03 (-5.36%)

0.634

-0.09 (-11.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26
Earnings (Next)03-24
Inst Owners14.25%
Inst Owner Change3.77%
Ins Owners29.81%
Ins Owner ChangeN/A
Market Cap8.10M
Revenue(TTM)2.48M
Net Income(TTM)-12.16M
Analysts82.5
Price Target11.73 (1750.16%)
Short Float %1.23%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-183.43%
Min EPS beat(2)-270.78%
Max EPS beat(2)-96.08%
EPS beat(4)0
Avg EPS beat(4)-151.67%
Min EPS beat(4)-270.78%
Max EPS beat(4)-21.21%
EPS beat(8)0
Avg EPS beat(8)-113.94%
EPS beat(12)1
Avg EPS beat(12)164.56%
EPS beat(16)1
Avg EPS beat(16)88.54%
Revenue beat(2)0
Avg Revenue beat(2)-95.77%
Min Revenue beat(2)-98.44%
Max Revenue beat(2)-93.1%
Revenue beat(4)0
Avg Revenue beat(4)-69.54%
Min Revenue beat(4)-98.44%
Max Revenue beat(4)-23.83%
Revenue beat(8)0
Avg Revenue beat(8)-74.59%
Revenue beat(12)3
Avg Revenue beat(12)-42.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.27
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.19
BVpS0.73
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.31%
ROE -130.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.03%
FCFM N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.68%
Cap/Sales 2.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.66
Quick Ratio 3.45
Altman-Z -13.04
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.95%
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue 1Y (TTM)280.77%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1825%
Revenue Next Year422.12%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-164.01%
OCF growth 3YN/A
OCF growth 5YN/A

COLLPLANT BIOTECHNOLOGIES LT / CLGN FAQ

What is the fundamental rating for CLGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLGN.


What is the valuation status for CLGN stock?

ChartMill assigns a valuation rating of 1 / 10 to COLLPLANT BIOTECHNOLOGIES LT (CLGN). This can be considered as Overvalued.


Can you provide the profitability details for COLLPLANT BIOTECHNOLOGIES LT?

COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a profitability rating of 1 / 10.


What is the expected EPS growth for COLLPLANT BIOTECHNOLOGIES LT (CLGN) stock?

The Earnings per Share (EPS) of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is expected to grow by 77.99% in the next year.